LSTA Lisata Therapeutics, Inc.
Price Chart
Executive Summary
Lisata Therapeutics announced that Kuva Acquisition Corp. has commenced a tender offer to acquire all outstanding shares for $4.00 per share in cash plus a non-tradeable contingent value right (CVR) worth up to an additional $3.00 per share upon achieving specified milestones. The transaction values Lisata at a significant premium to its historical market price and is expected to close in Q3 2026, though financing for the offer price has not yet been committed.
Key Financial Metrics
Actionable Insight
Traders should monitor the tender offer period (expires July 10, 2026) and any financing commitments from Kuva. The lack of committed financing introduces execution risk; if financing falls through, the deal may not close. The CVR milestones (Phase 2a GBM trial enrollment and NDA filing) are binary events that could provide additional upside if achieved.
Key Facts
- Kuva Acquisition Corp. commenced a tender offer to buy all Lisata shares for $4.00 per share in cash plus a CVR worth up to $3.00 per share.
- The CVR includes a $1.25 payment upon achieving the First Milestone (enrollment/completion of a Phase 2a GBM trial) and a $1.75 payment upon the Second Milestone (NDA filing for certepetide).
- The tender offer expires on July 10, 2026, unless extended.
- The transaction is expected to close in Q3 2026, subject to customary conditions including a majority of shares tendered.
- Lisata's Board unanimously recommends stockholders tender their shares.
- Kuva does not have committed financing to fund the offer price; it intends to use debt/equity financings or credit facilities.
- Following the tender, untendered shares will be acquired in a second-step merger for the same consideration.
Financial Impact
Total upfront consideration of $4.00 per share in cash plus CVR with potential additional $3.00 per share, totaling up to $7.00 per share if both milestones are achieved.
Risk Factors
- Kuva has no committed financing to fund the offer price, creating risk of deal failure if financing is not secured.
- CVR milestones may not be achieved, resulting in no additional payments.
- Potential competing offers or stockholder litigation could delay or derail the transaction.
- Delisting from Nasdaq and deregistration will reduce liquidity for remaining shareholders.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3309632 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
3d ago
|
Press Release
| $3.45 awaiting T+5 | awaiting T+5 | — | $3.56 (+3.34%) |
|
Jun 9, 2026
4d ago
|
8-K
| $3.45 awaiting T+5 | awaiting T+5 | — | $3.56 (−3.34%) |
|
Jun 1, 2026
12d ago
|
8-K
| $3.58 $3.35 | ▲ +6.42% | ▲ +3.67% | $3.56 (+0.56%) |
|
May 29, 2026
14d ago
|
8-K
| $3.58 $3.35 | ▼ −6.42% | ▼ −3.67% | $3.56 (−0.56%) |
|
Apr 15, 2026
8w ago
|
8-K
| $3.37 $3.33 | ▲ +1.19% | ▲ +2.17% | $3.56 (−5.64%) |
|
Mar 6, 2026
14w ago
|
Press Release
| $5.04 $5.04 | · 0.00% | ▲ +1.35% | $3.56 (−29.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access